¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Poisoning by systemic antibiotics"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® antibiotics ÇÑ±Û Ç×»ýÁ¦
¼³¸í   
  ¹Ì»ý¹°ÀÌ ¸¸µé¾î³»´Â Ç×»ý ¹°Áú·Î µÈ ¾àÁ¦. ´Ù¸¥ ¹Ì»ý¹°À̳ª »ý¹° ¼¼Æ÷¸¦ ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦Çϰųª Á×ÀδÙ. ¹Ì»ý¹°¿¡ ÀÇÇØ »ý»êµÇ¸ç ¹Ì»ý¹°ÀÇ ¹ßÀ° ¶Ç´Â ¾Ç¼ºÁ¾¾çÀÇ Áõ½ÄÀ» ÀúÁöÇϴ ¹°ÁúÀÌ´Ù. ¼÷ÁÖ¿¡ ¹«ÇØÇÑ Ç×»ý¹°ÁúÀº »ç¶÷-µ¿¹°-½Ä¹°ÀÇ ¼¼±Õ°¨¿°ÁõÀÇ Ä¡·á¿¡ È­Çпä¹ýÁ¦·Î »ç¿ëÇÑ´Ù. ±× ÀÛ¿ë¸ÞÄ¿´ÏÁòÀº ¹Ì»ý¹°ÀÇ ¼¼Æ÷º®À» ÇÕ¼ºÇϴ °ÍÀ» ÀúÇØÇϴ °Í, ÇÙ»ê(DNA, RNA) ÇÕ¼ºÀúÇØ, ´Ü¹éÁú ÇÕ¼ºÀúÇØ, º¸È¿¼ÒÇÕ¼ºÀúÇØ µîÀÌ ÀÖ´Ù. ÀÛ¿ë¸ÞÄ¿´ÏÁò°ú È­Çб¸Á¶¿¡ µû¶ó ¥â-¶ôްè(Æä´Ï½Ç¸°·ù), ¾Æ¹Ì³ë´ç·ù°è, Åׯ®¶ó»çÀÌŬ¸°°è, Å¬·Î¶÷Æä´ÏÄݰè, Æú¸®ÆéƼµå°è, ±âŸ(¸°ÄÚ¸¶À̽Å, ¹ÝÄÚ¸¶À̽еî)·Î ºÐ·ùµÈ´Ù. Ç×Á¾¾çÇ×»ý¹°Áú¿¡´Â ¾Æµå¸®¾Æ¸¶À̽Å, ¾ÇƼ³ë¸¶À̽ÅD, ¸¶ÀÌÅ丶À̽ÅC, ºí·¹¿À¸¶À̽еîÀÌ ÀÖ´Ù.
¿µ¹® systemic lupus erythematosus ÇÑ±Û Àü½ÅÈ«¹Ý·çǪ½º
¼³¸í   
  Àü½Å ÀÚ°¡¸é¿ªº´ÀÇ ´ëÇ¥Àû º´ÀÌ´Ù. ¿©¼º¿¡°Ô ¾ÐµµÀûÀ¸·Î ¸¹°í, 10~39¼¼±îÁö°¡ 70%¸¦ Â÷ÁöÇÑ´Ù. ¿øÀÎÀº Àß ¸ð¸£³ª ÀÚ°¡¸é¿ª Á¶Àý±â´É¿¡ Àå¾Ö°¡ Àִ °ÍÀ¸·Î »ý°¢µÈ´Ù. À¯Àü¿äÀÎ, È£¸£¸óÀÇ ¿µÇâ, È¯°æ¿ä¼Ò°¡ Á¾ÇÕÀûÀ¸·Î º¸Á¶ T¼¼Æ÷¿Í B¼¼Æ÷¸¦ È°¼ºÈ­½ÃÄѼ­ ¿©·¯ °¡Áö ÀÚ°¡Ç×üµé, Áï Ãµ¿¬ DNA, ÀÌÁß°¡´Ú DNA, ¿Ü°¡´Ú DNA, RNA, ÇٴܹéÁú µî°ú °°Àº ÇÙ Ç׿ø¿¡ ´ëÇÑ Ç×ü, ºñÇÙÇ׿ø¿¡ ´ëÇÑ ¿©·¯ °¡Áö Ç×ü°¡ ½ñ¾ÆÁ® ³ª¿Â´Ù. ÀÌ Áß ÀÌÁß°¡´Ú DNA¸¦ Æ÷ÇÔÇÑ ¼øÈ¯¸é¿ªº¹ÇÕü°¡ ÄáÆÏ¿¡ Ä§ÂøÇÏ¿© ¼Õ»óÀ» ÀÏÀ¸Å°´Âµ¥ °ü¿©ÇÑ´Ù. DNA¿Í ¿©·¯ °¡Áö ¼¼Æ÷¼ººÐ¿¡ ´ëÇÑ ÀÚ°¡¸é¿ªÁúȯÀ¸·Î ÀüÄáÆÏ±â¸¦ Ä§¹üÇÏ¿© ¿°ÁõÀ» ÀÏÀ¸Å²´Ù. ¿©·¯ ÀÚ°¡Ç׿ø¿¡ ´ëÇÑ ¸é¿ª¹ÝÀÀ¿¡ ÀÇÇÑ Ç×üÀÇÁ¸¼º ¸é¿ª¹ÝÀÀ°ú ¸é¿ªº¹ÇÕü ¹ÝÀÀÀ¸·Î Å丮ÄáÆÏ¿°, Ç÷°ü¿°, °üÀý¿° ¹× ºóÇ÷À» µ¿¹ÝÇÑ´Ù.
¿µ¹® systemic circulation ÇÑ±Û Ã¼¼øÈ¯
¼³¸í   
  ¿Þ½É½Ç¿¡¼­ ½Åü¸¦ µ¹¾Æ ¿À¸¥½É¹æ±îÁöÀÇ ¼øÈ¯À» ÀǹÌÇϸç, ¿Þ½É½Ç ¡æ ´ëµ¿¸Æ ¡æ µ¿¸Æ ¡æ ¸ð¼¼Ç÷°ü ¡æ Á¤¸Æ ¡æ ´ëÁ¤¸Æ ¡æ ¿À¸¥½É¹æÀǠȸ·Î¸¦ ¼øÈ¯ÇÑ´Ù.
¿µ¹® lead poisoning, saturinism ÇÑ±Û ³³Áßµ¶
¼³¸í   
  ¿ëÇØ¼º ³³À» ÈíÀÔÇϰųª »ïÅ´À¸·Î½á À¯¹ßµÇ´Â Á÷¾÷º´. ±Þ¼º°ú ¸¸¼ºÀÌ ÀÖÀ¸¸ç ´ë·®À¸·Î Èí¼öÇÏ¿© ±Þ¼º À§Àå¿° Áõ»óÀ» ³ªÅ¸³»´Â ±Þ¼º Áßµ¶Àº ¿ÀÈ÷·Á µå¹°°í, ±Ø¼Ò·®(1ÀÏ 1mg ÀÌÇÏ)ÀÇ ³³À» Àå±â°£ Áö¼ÓÀûÀ¸·Î ¼·ÃëÇÔÀ¸·Î½á »ý±â´Â ¸¸¼ºÀÌ ´õ ½É°¢ÇÏ´Ù. ³³Á¦·Ã¾÷-ȰÆÇÀμâ¾÷-µµÀå¾÷-³³À¯¸®Á¦Á¶¾÷-ÃàÀüÁöÁ¦Á¶¾÷ µî ³³ ¶Ç´Â ³³À» ÇÔÀ¯ÇÑ ¹°ÁúÀ» ´Ù·ç´Â »ç¶÷, ¶Ç °ú°Å¿¡´Â ¿¬¹éÀ» »ç¿ëÇÑ ºÐ¿¡ ÀÇÇÑ È­Àåµ¶ÀÌ ¿©¼º¿¡°Ô ³ªÅ¸³ª ¹®Á¦°¡ µÇ¾úÀ¸³ª, ¿À´Ã³¯¿¡´Â °¡¼Ö¸°¿¡ È¥ÇյȠ¾ÈƼ³ìÁ¦ÀΠ»ç¿¡Æ¿³³À¸·Î ÀÎÇÑ Áßµ¶ÀÌ ÁÖ¸ñµÇ°í ÀÖ´Ù. »ç¿¡Æ¿³³ Áßµ¶ÀÇ Áõ»óÀº ¿©·¯ °¡ÁöÀε¥, ºóÇ÷À̳ª ¶³¸®´Â Áõ»óÀÌ ºñ±³Àû Ãʱ⿡ ³ªÅ¸³ª°í ³³¼±(ÀÕ¸ö¿¡ ³³ÀÌ Ä§ÂøÇÏ¿© Ã»È¸¹é»öÀ¸·Î Âø»öµÈ´Ù)À̳ª ¹ßÀÛÀû º¹ÅëÀ̠Ư¡ÀÌ´Ù. ÀϹÝÀûÀ¸·Î ³³ÀÇ Áõ±â³ª °¡·ç°¡ ±âµµ¸¦ ÅëÇØ Ã¼³»·Î µé¾î°¡´Â °æ¿ì°¡ µµ·á-¾È·á¿¡ µé¾î Àִ ³³ÀÌ ÇǺγª ¼ÒÈ­°üÀ» ÅëÇØ Ä§ÅõÇϴ Áõ·Êº¸´Ù Áõ»óÀÌ ½ÉÇÏ´Ù.
¿µ¹® food poisoning ÇÑ±Û ½ÄÁßµ¶
¼³¸í   
  À¯Çع°Áú¿¡ ¿À¿°µÈ À½½Ä¹°À» ¸ÔÀ½À¸·Î½á ÀϾ´Â ÀϱºÀÇ ±Þ¼ºÁúȯÀ̸ç, ÁַΠ¹ß¿­-±¸¿ªÁú-±¸Åä-¼³»ç-º¹Åë µîÀÇ Áõ¼¼°¡ ³ªÅ¸³­´Ù. ÀÔÀ» ÅëÇÑ Àü¿°º´À̳ª ±â»ýÃæº´ µîÀº ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾Ê´Â´Ù. ½ÄÁßµ¶À» ¿øÀι°Áú¿¡ µû¶ó ºÐ·ùÇϸ頼¼±Õ¼º ½ÄÁßµ¶, È­Çмº ½ÄÁßµ¶, ÀÚ¿¬µ¶ ½ÄÁßµ¶, ¹Ì»ý¹° µ¶¼º´ë»ç¹°Áú¿¡ ÀÇÇÑ ½ÄÁßµ¶À¸·Î ±¸ºÐÇÒ ¼ö ÀÖ´Ù. °¢ ºÎ·ù¿¡ ¼ÓÇϴ µ¶¼º¹°ÁúÀº ±× Á¾·ù°¡ ¸Å¿ì ¸¹À¸¸ç, µ¶¼º¹°ÁúÀº ´çÀ堰ǰ­À» ÇØÄ¥¸¸ÇÑ ¾çÀÌ ¾Æ´Ï¶ó ÇÏ´õ¶óµµ ¸¹Àº ½Äǰ Áß¿¡ ³Î¸® ºÐÆ÷µÇ¾î À־ ¸¸¼ºÁßµ¶-¹ß¾Ï¼º-µ¹¿¬º¯ÀÌ À¯¹ß¼º-±âÇüÀ¯¹ß¼º-¾Ë·¹¸£±â¼º ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ¿øÀÎÀÌ µÉ ¼öµµ ÀÖ´Ù. ½ÄÁßµ¶ÀÇ ´ëºÎºÐÀº ¼¼±Õ¿¡ ÀÇÇÏ¿© »ý±â´Â ¼¼±Õ¼º ½ÄÁßµ¶À¸·Î¼­, ¿©±â¿¡´Â »ì¸ð³Ú¶ó-Àåºñºê¸®¿À-À£Ä¡±Õ-º´¿ø´ëÀå±Õ¿¡ ÀÇÇÑ °¨¿°Çü ½ÄÁßµ¶°ú Æ÷µµ¾Ë±Õ, º¸Å縮´©½º±ÕÀÌ »ý¼ºÇÑ µ¶¼Ò¿¡ ÀÇÇÑ µ¶¼ÒÇü ½ÄÁßµ¶ÀÌ ÀÖ´Ù. °¨¿°Çü ½ÄÁßµ¶Àº »ì¾Æ Àִ À¯Çؼ¼±ÕÀ» ´Ù·®À¸·Î ¸ÔÀ½À¸·Î½á ÀϾ´Â °ÍÀ̹ǷΠ½ÄǰÀ» °¡¿­Çؼ­ ¸ÔÀ¸¸é ¼¼±ÕÀº »ç¸êÇØ ¹ö¸®±â ¶§¹®¿¡ Áßµ¶µÇ´Â ÀÏÀÌ ¾ø´Ù. ±×·¯³ª µ¶¼ÒÇü ½ÄÁßµ¶Àº ¼¼±ÕÀº Á׾ µ¶¼Ò´Â ±×´ë·Î ³²¾Æ ÀÖÀ¸¹Ç·Î À½½Ä¹°À» °¡¿­Çصµ ³²Àº µ¶¼Ò°¡ Áßµ¶À» ÀÏÀ¸Å°´Â °æ¿ìÀÌ´Ù. È­Çмº ½ÄÁßµ¶Àº È­Çй°Áú¿¡ ÀÇÇÑ °ÍÀ¸·Î¼­ ±Ù·¡¿¡ µé¾î¿Í È­Çаø¾÷ÀÇ ¹ß´Þ·Î È­ÇÐÀû ÇÕ¼ºÇ°ÀÇ ´ë·®»ý»êÀÌ °¡´ÉÇØÁö°í À̵éÀÌ ½Äǰ°ø¾÷À̳ª ³ó¾÷ºÐ¾ß¿¡ ´Ù·®À¸·Î »ç¿ëµÇ¸é¼­ ½É°¢ÇÑ ¹®Á¦·Î µîÀåÇÏ¿´´Ù. Æ¯È÷ ½Äǰ°¡°ø°úÁ¤ Áß¿¡ »ç¿ëÇÑ ºÒ¹ý½Äǰ÷°¡¹°, ÀÜ·ù³ó¾à-»ê¾÷Æó¼ö¿¡ ÀÇÇÑ ½ÄǰÀÇ Á߱ݼӿÀ¿°, ¶Ç´Â ½Äǰ°ú °ü·ÃÀÌ Àִ °¢Á¾ ¿ë±â-±â±¸-Æ÷À堵¼­ ¿ëÃâµÇ´Â µ¶¼º¹°ÁúÀÌ ¹®Á¦°¡ µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bullous systemic lupus erythematosus
    ¹°ÁýÀü½ÅÈ«¹Ý·çǪ½º
  • diffuse systemic sclerosis
    ±¤¹üÀ§Àü½Å°æÈ­Áõ
  • idiopathic systemic fibrosis
    Ư¹ßÀü½Å¼¶À¯Áõ
  • portal-systemic encephalopathy
    ¹®¸ÆÀü½Å¼øÈ¯(¼º)³úº´(Áõ)
  • progressive systemic sclerosis
    ÁøÇàÀü½Å°æÈ­Áõ
  • systemic
    1. Àü½Å¼º- 2. ü°èÀû
  • systemic amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • systemic circulation
    ¿Â¸ö¼øÈ¯, ü¼øÈ¯
  • systemic death
    Àü½Å»ç¸Á
  • systemic disease
    Àü½Åº´
  • systemic embolism
    Àü½Å»öÀüÁõ
  • systemic hypotension
    Àü½ÅÀúÇ÷¾Ð
  • systemic infection
    Àü½Å°¨¿°
  • systemic inflammatory response syndrome
    Àü½Å¿°Áõ¹ÝÀÀÁõÈıº
  • systemic lesion
    °èÅ뺴ÅÍ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • poisoning
    Áßµ¶
  • lead poisoning
    ³³Áßµ¶
  • staphylococcal food poisoning
    Æ÷µµ¾Ë±Õ½ÄÁßµ¶
  • streptococcus food poisoning
    »ç½½¾Ë±Õ½ÄÁßµ¶, ¿¬¼â±¸±Õ½ÄÁßµ¶
  • systemic circulation
    ¿Â¸ö¼øÈ¯, ü¼øÈ¯
  • systemic disease
    Àü½Åº´
  • systemic embolism
    Àü½Å»öÀüÁõ
  • systemic hypotension
    Àü½ÅÀúÇ÷¾Ð
  • systemic infection
    Àü½Å°¨¿°
  • systemic erythematosus lupus
    Àü½ÅÈ«¹Ý·çǪ½º
  • systemic reaction
    Àü½Å¹ÝÀÀ
  • systemic sclerosis
    Àü½Å°æÈ­Áõ
  • systemic inflammatory response syndrome
    Àü½Å¿°Áõ¹ÝÀÀÁõÈıº
  • systemic treatment
    Àü½ÅÄ¡·á
  • systemic therapy
    Àü½Å¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carbon monoxide poisoning
    ÀÏ»êȭź¼ÒÁßµ¶
  • corrosive poisoning
    ½ÂÈ«Áßµ¶, ºÎ½Ä¾à¹°Áßµ¶
  • crowd poisoning
    ±ºÁýÁßµ¶
  • food poisoning
    ½ÄÁßµ¶
  • lead poisoning
    ³³Áßµ¶
  • organophosphate poisoning
    À¯±âÀλ꿰Áßµ¶
  • poisoning
    Áßµ¶
  • plumbism poisoning
    (¢¡lead poisoning) ³³Áßµ¶
  • systemic amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • systemic arachnidism
    Àü½Å°Å¹Ìµ¶Áõ
  • bullous systemic l. erythematosusv lupus
    ¹°ÁýÀü½ÅÈ«¹Ý·çÇÁ½º
  • systemic circulation
    ¿Â¸ö¼øÈ¯, ü¼øÈ¯
  • diffuse systemic sclerosis
    ±¤¹üÀ§Àü½Å°æÈ­Áõ
  • systemic death
    Àü½Å»ç
  • systemic disease
    Àü½Åº´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibiotics
    Ç×»ýÁ¦(ù÷ßæð¥)
  • Lupus erythematosus(LE), systemic
    Àü½Å¼ºÈ«¹Ý¼º ·çǪ½º.
  • SLE= systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º ·çǪ½º.
  • acute systemic lupus erythematosus = ASLE
    ±Þ¼º Àü½Å¼º È«¹Ý¼º ³¶Ã¢(¡­îïãóàõûõÚèàõÕÉóê)
  • acute systemic lupus erythematosus =ASLE
    ±Þ¼º Àü½Å¼º È«¹Ý¼º ³¶Ã¢(¡­îïãóàõûõÚèàõÕÉóê).
  • anomalies of systemic venous return
    ´ëÁ¤¸ÆÈ¯·ù(ÓÞð¡Øæü½êü)ÀÌ»ó.
  • anomalies of systemic venous return
    ´ëÁ¤¸ÆÈ¯·ù(ËÀ?ËÎÌ·Ëô)ÀÌ»ó.
  • idiopathic systemic fibrosis
    Àü½Å¼º Ư¹ß¼º(îïãóàõ ÷åÛ¡àõ) ¼¶À¯Áõ
  • infantile systemic hyalinosis
    ¿µ¾Æ Àü½Å¼º À¯¸®ÁúÁõ
  • infection, systemic
    Àü½Å°¨¿°
  • portal-systemic encephlopathy
    ¹®¸Æ-Àü½Å¼øÈ¯¼º ³úº´Áõ(Ú¦Øæ-îïãóâàü»àõ ÒàÜ»ñø)
  • porto-systemic shunt
    ¹®¸ÆÃ¼´Ü¶ô(Ó­Õ©)<--¼ÇÆ®>
  • primary systemic amyloidosis
    ¿ø¹ß¼º Àü½Å À¯ÀüºÐÁõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å °æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(Ìãûùñø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibiotics
    Ç×»ýÁ¦(ù÷ßæð¥)
  • bacteriostatic antibiotics
    Á¤±Õ¼º Ç×»ý¹°Áú(¡­àõù÷ßæÚªòõ).
  • beta-lactam antibiotics
    º£Å¸-¶ôŽÇ×»ýÁ¦.
  • intestinal antibiotics
    Àå°ü¿ë Ç×»ý¹°Áú(íóηéÄ ù÷ßæÚªòõ).
  • intestinal antibiotics
    Àå°ü¿ë Ç×»ý¹°Áú(íóηéÄù÷ßæÚªòõ).
  • peptide antibiotics
    ÆÕƼµåÇ×»ýÁ¦
  • prophylactic antibiotics
    ¿¹¹æÀû Ç×»ýÁ¦
  • resistance to antibiotics
    Ç×»ýÁ¦ÀúÇ×¼º(ù÷ßæð¥î½ù÷àõ), Ç×»ýÁ¦³»¼º(ù÷ßæð¥ Ò±àõ).
  • acute systemic lupus erythematosus = ASLE
    ±Þ¼º Àü½Å¼º È«¹Ý¼º ³¶Ã¢(¡­îïãóàõûõÚèàõÕÉóê)
  • acute systemic lupus erythematosus =ASLE
    ±Þ¼º Àü½Å¼º È«¹Ý¼º ³¶Ã¢(¡­îïãóàõûõÚèàõÕÉóê).
  • anomalies of systemic venous return
    ´ëÁ¤¸ÆÈ¯·ù(ÓÞð¡Øæü½êü)ÀÌ»ó.
  • anomalies of systemic venous return
    ´ëÁ¤¸ÆÈ¯·ù(ËÀ?ËÎÌ·Ëô)ÀÌ»ó.
  • bullous systemic lupus erythematosus
    ¼öÆ÷¼º Àü½Å¼º È«¹Ý¼º ·çǪ½º
  • cutaneous systemic vasculitis
    ÇǺΠÀü½Å¼º(ù«Ý± îïãóàõ) Ç÷°ü¿°(úìηæú)
  • diffuse systemic sclerosis
    ±¤¹üÀ§ Àü½Å °æÈ­Áõ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • poisoning
    "Áßµ¶(ñéÔ¸), Áßµ¶ÀÛ¿ë(ñéÔ¸íÂéÄ)"
  • aminoglycoside antibiotics
    ¾Æ¹Ì³ë±Û¶óÀÌÄÚ»çÀ̵å Ç×»ýÁ¦(ù÷ßæð¥)
  • antitumor antibiotics
    Ç×Á¾¾ç Ç×»ýÁ¦(ù÷ðþåËù÷ßæð¥)
  • beta lactam antibiotics
    º£Å¸ ¶ôŽ Ç×»ýÁ¦(ù÷ßæð¥)
  • depsipeptide antibiotics
    µª½ÃÆéŸÀ̵å Ç×»ýÁ¦(ù÷ßæð¥)
  • ion-translocating antibiotics
    ÀÌ¿ÂÀüÀ§ Ç×»ýÁ¦(ï®êÈù÷ßæð¥)
  • purine antibiotics
    Ç»¸° Ç×»ýÁ¦(ù÷ßæð¥)
  • pyrimidine antibiotics
    ÇǸ®¹Ìµò Ç×»ýÁ¦(ù÷ßæð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • broadsoectrum antibiotics
    ±¤¹üÀ§Ç×»ýÁ¦
  • carbon monoxide poisoning
    ÀÏ»êȭź¼ÒÁßµ¶
  • CO-poisoning
    ÀÏ»êȭź¼ÒÁßµ¶
  • food poisoning
    ½ÄÁßµ¶
  • systemic
    Àü½Å¼ºÀÇ
  • systemic blood pressure
    üÇ÷¾Ð
  • systemic infection
    Àü½Å¼º°¨¿°(Áõ)
  • systemic lesion
    Àü½Å¼ºº´º¯
  • systemic lupus erythematosus
    Àü½Å¼ºÈ«¹Ý¼º·çǪ½º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TEF Tracheo-Esophageal Fistula
  ? Tx
    1. Infant Warmer
 ...
NOABX no antibiotics
ORALABX oral antibiotics
PSS painful shoulder syndrome; physiologic saline solution; porcine stress syndrome; primary Sjogren syn...
SMCD senile macular choroidal degeneration; systemic mast cell disease; systemic meningococcal disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AGs Aminoglycoside antibiotics
AB Antibiotics
DSP Diarrhetic Shellfish Poisoning
PSP Paralytic Shellfish Poisoning
MAP Mean systemic arterial pressure
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • T36
    Poisoning by systemic antibiotics
    Àü½Å Ç×»ýÁ¦¿¡ ÀÇÇÑ Áßµ¶
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • aminoglycoside antibiotics
    ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵å Ç×»ýÁ¦
    ½ºÅ×·¾Å丶À̽Å, °¡³ª¸¶À̽Å, °ÕŸ¸¶À̽Å, ¾Æ¹ÌÄ«½Å, Åäºê¶ó¸¶À̽еîÀÌ ÀÖ´Ù. ±¤¹üÀ§ Ç×±Õ ½ºÆåÆ®·³À» Áö´Ï°í ±×¶÷ À½¼º °£±Õ¿¡ ´ëÇØ¼­µµ È¿°úÀûÀÌ´Ù. ƯÈ÷ Ç׻꼺 ±Õ¿¡ È¿°úÀûÀ̰í PAS³ª INAH¿Í º´¿ëÇØ¼­ Ä¡·á¿¡ »ç¿ëµÈ´Ù.
  • antibiotics
    Ç×»ýÁ¦
    ¾î¶² »ý¹° ȤÀº ¹Ì»ý¹°¿¡¼­ »ý¼ºµÇ´Â ¹°Áú·Î¼­ ´Ù¸¥ ¹Ì»ý¹°ÀÇ ¼ºÀå ¹× ¹ßÀ°À» ¾ïÁ¦ ȤÀº »ç¸ê½ÃŰ´Â ¹°Áú. ¼÷ÁÖ¿¡ ¹«ÇØÇÑ È¯°æ ¹°ÁúÀº »ç¶÷, µ¿¹°, ½Ä¹°ÀÇ ¼¼±Õ °¨¿°Áõ Ä¡·áÀÇ È­Çпä¹ýÁ¦·Î »ç¿ëµÈ´Ù.
  • bacteriostatic antibiotics
    Á¤±Õ¼º Ç×»ý ¹°Áú
    ¼¼±ÕÀÇ ¹ßÀ°, Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â È¿°ú°¡ ÀÖ´Â Ç×»ý ¹°Áú.
  • beta-lactam antibiotics
    º£Å¸-¶ôŽ Ç×»ýÁ¦
  • broad spectrum antibiotics
    ±¤¹üÀ§ Ç×»ýÁ¦, ±¤¿ª Ç×»ýÁ¦
  • chloramphenicol group antibiotics
    Ŭ·Î¶÷Æä´ÏÄݱº Ç×»ýÁ¦
  • intestinal antibiotics
    Àå°ü¿ë Ç×»ý ¹°Áú
  • PCN-resistant-lactam antibiotics

    PDGF (Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ

  • portal-systemic venous collateral circulation
    °£ ¹®¸Æ-Àü½Å Á¤¸ÆÀÇ ÃøÁö ¼øÈ¯
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å °æÈ­Áõ, ÁøÇ༺ Àü½Å¼º °æÈ­Áõ, ÁøÇ༺ Àü½Å¼º °øÇÇÁõ
  • surgically contructed systemic-pulmonary shunts
    ¿Ü°úÀûÀ¸·Î Çü¼ºÇØÁØ Àü½Å-Æó¼º ´Ü¶ô
  • systemic adverse effect
    Àü½Å¼º ºÎÀÛ¿ë
  • systemic blood pressure
    üÇ÷¾Ð
  • systemic circulation
    ´ë¼øÈ¯, ü¼øÈ¯
    ½ÉÀåÀÇ Á½ɽǿ¡¼­ ´ëµ¿¸ÆÀ¸·Î ³ª°£ Ç÷¾×ÀÌ Àü½ÅÀ» ÇÑ ¹ÙÄû µ· ´ÙÀ½, ´ëÁ¤¸ÆÀ» ÅëÇØ ¿ì½É¹æÀ¸·Î µ¹¾Æ¿À´Â ¼øÈ¯. ü¼øÈ¯À̶ó°íµµ ÇÑ´Ù. À̰ÍÀº Æó ¼øÈ¯À» ¼Ò¼øÈ¯À̶ó°í ÇÏ´Â °Í°ú ºñ±³ÇÏ¿© ºÙÀÎ ¸íĪÀÌ´Ù. Á½ɽǿ¡¼­ ´ëµ¿¸ÆÀ¸·Î ³ª¿Í ¼Òµ¿¸Æ, ¸ð¼¼Ç÷°üÀ» Áö³ª ¼ÒÁ¤¸Æ, ´ëÁ¤¸ÆÀ» °æÀ¯ÇÏ¿© ¿ì½É¹æÀ¸·Î µ¹¾Æ¿À´Â °æ·ÎÀÌ´Ù. ¼ÒÈ­±â °èÅë¿¡¼­ ³ª¿Â Á¤¸ÆÇ÷Àº ¹®¸Æ¿¡ ¸ð¿© °£À¸·Î µé¾î°¬´Ù°¡ ´Ù½Ã ¸ð¼¼Ç÷°üÀ¸·Î °¥¶óÁø ´ÙÀ½ °£Á¤¸ÆÀ¸·Î µé¾î°£´Ù.
  • systemic degenerative joint disease
    Àü½Å¼º ÅðÇ༺ °üÀý Áúȯ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
systemic poisoning Any disease of toxic origin.
Synonym: systemic poisoning.
Origin: toxico-+ G. -osis, condition
(05 Mar 2000)
antibiotics Drugs that fight infections.
(12 Dec 1998)
antibiotics, aminoglycoside Antibiotics whose structure contains amino sugars attached to an aminocyclitol ring (hexose nucleus) by glycosidic bonds. Aminoglycoside antibiotics are derived from various species of streptomyces and micromonospora or are produced synthetically. They act by inhibiting protein synthesis.
(12 Dec 1998)
antibiotics, anthracycline Antibiotics which have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to a sugar molecule. These antibiotics have potent antineoplastic activity. The two best known members of this group are daunorubicin and doxorubicin. Since these agents intercalate with DNA, many DNA functions are adversely affected. Futhermore they interact with cell membranes thereby altering their functions and also generate hydrogen peroxide and hydroxy radicals which are highly destructive to cells.
(12 Dec 1998)
antibiotics, antifungal Antibiotics inhibiting the growth of or killing fungi and used in the treatment of various fungal diseases.
(12 Dec 1998)
antibiotics, antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the development of neoplasms.
(12 Dec 1998)
antibiotics, antitubercular Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.
(12 Dec 1998)
antibiotics, combined Combination of antibiotics used against difficult-to-treat infections. Antibiotic combinations have been used mainly to broaden the antibacterial spectrum and prevent development of resistance. In some instances these combinations have shown lower toxicity, but drug antagonism may be one of the problems encountered by their use. They may be given simultaneously or sequentially. The drugs need not be in the same dosage form.
(12 Dec 1998)
antibiotics, glycopeptide Antibiotics whose structure contains one or more cyclic peptides to which are attached one or more deoxy sugars in glycosidic linkage. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls.
(12 Dec 1998)
antibiotics, lactam Compounds containing a four-membered ring with an amide nitrogen and a keto group. This configuration includes bacteriostatic, cell-wall inhibiting antibiotics, such as penicillins and cephalosporins; their analogs and derivatives, such as the penem (or penam) compounds; clavulanic acids; and monobactams. They are substrates for and may act as inhibitors of bacterial beta-lactamases.
(12 Dec 1998)
antibiotics, macrolide A group of antibiotics containing a macrocyclic lactone ring linked glycosidically to one or more sugar moieties. These antibiotics are produced by certain species of streptomyces. They often inhibit protein synthesis by binding to the 50s subunits of 70s ribosomes.
(12 Dec 1998)
antibiotics, peptide Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls.
(12 Dec 1998)
antibiotics, tetracycline <chemical> Broad-spectrum natural and semisynthetic antibiotics with a naphthacene structure obtained from various streptomyces species.
Pharmacological action: protein synthesis inhibitor.
(12 Dec 1998)
intravenous antibiotics The administration of an antibiotic solution into the venous circulation.
(27 Sep 1997)
topical antibiotics A ointment (or cream) based medication that kills bacteria.
Examples include Neosporin, Bactroban, Garamycin, bacitracin, gentamicin, mupirocin, neomycin, silver sulphasalazine, chloramphenicol and clindamycin.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • systemic
    °èÅëÀÇ
  • systemic
    Á¶Á÷(°èÅë)ÀÇ;Àü½ÅÀÇ
  • blood poisoning
    ÆÐÇ÷Áõ
  • food poisoning
    ½ÄÁßµ¶
  • gas poisoning
    °¡½º Áßµ¶
  • lead poisoning
    ³³Áßµ¶;¿¬µ¶
  • lead poisoning
    ¿¬µ¶;³³Áßµ¶
  • mercury poisoning
    ¼öÀº Áßµ¶
  • poisoning
    Áßµ¶
  • ptomaine poisoning
    ÇÁÅ丶ÀÎ Áßµ¶;(ÀϹÝÀûÀ¸·Î)½ÄÁßµ¶
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á